– USA, UT – Seek Labs, a healthcare innovations company developing next-generation molecular diagnostic systems and novel CRISPR-based gene therapies, today announced the appointment of Cindy Dunkle to its Board of Directors, effective February 27, 2024, bringing decades of life sciences leadership experience and connections that will enhance Seek Labs’ strategic direction and employee-centered approach.
About Cindy Dunkle
Cindy Dunkle is widely recognized for her profound understanding of human capital management in the life sciences sector. She is CPO for Denali Therapeutics, a clinical-stage biopharmaceutical company developing therapeutics for neurodegenerative diseases. As CPO, Dunkle oversees human resources, company facilities, and environmental health and safety. Her leadership has been key to the company’s growth and talent acquisition strategy. Dunkle was a key part of the organization and strategy through the company’s IPO in 2017, which was the largest in the biotech industry that year.
Cindy Dunkle is an established player in the life sciences industry with important insights into bringing healthcare innovations and solutions to patients. With a career spanning over 30 years, Dunkle is a trusted advisor and advocate for employees, understanding their needs while aligning them with organizational objectives. In 2022, she was named one of the Top 25 Women Leaders in Biotechnology by The Healthcare Technology Report. She has also been featured on PharmaVoice’s Woman of the Week podcast where she was recognized as a catalyst for change in the life sciences industry.
Jared Bauer, CEO, expressed his enthusiasm to have Dunkle join Seek Labs’ Board: “We are thrilled to have Cindy Dunkle join our Board of Directors. Cindy is renowned in our industry for her commitment to innovation and employee engagement. We are excited to leverage her experience and network to ensure that Seek Labs continues to foster innovative technologies that meet the needs of patients globally.”
Dunkle received a B.S. in Psychology from Metropolitan State University. Before her role at Denali, she held key HR roles at Adverum Biotechnologies and Genentech. Dunkle currently serves on the Board of Managers for Life Science Cares Bay Area, a collective of Bay Area life sciences companies to address poverty and inequality locally. Additionally, Dunkle is Vice-Chair of BioHive, a public-private nonprofit representing Utah’s collective of life sciences and healthcare innovation companies.
“I am honored to join Seek Labs’ Board of Directors at a pivotal moment as the company continues to grow and expand its footprint in the life sciences and biotechnology industry,” said Cindy Dunkle. “I am excited to drive Seek Labs’ strategic initiatives in pharmaceuticals and other biotechnology innovations.”
About Seek Labs
Seek Labs is a company united by a vision to advance scientific discovery and universal solutions. Seek Labs strives to innovate healthcare solutions that bridge gaps between patients, providers, and treatments. Seek Labs is united by the passion of our founders and their shared beliefs that healthcare solutions should empower individuals and serve their specific needs. Today—after years of experimentation, failure, and breakthrough— Seek Labs is developing new solutions for point-of-care diagnostics and CRISPR-based pharmaceutical technologies that have the potential to revolutionize the detection and treatment of diseases.
Seek Labs is headquartered in Salt Lake City, Utah. Seek Labs is a proud member of the BioHive, a collective representing the life science and healthcare innovation ecosystem in Utah. BioHive is dedicated to all the ways our work can positively impact the lives of our community, our teams, and our patients.
For more information: https://seeklabs.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
